Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis

Annals of the Rheumatic Diseases

Volumn 71, Issue 5, 2012, Pages 700-706

  Sieper, Joachim ^a   Van Der Heijde, Désirée ^b   Dougados, Maxime ^c   Brown, L Steve ^d   Lavie, Frederic ^e   Pangan, Aileen L ^d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ABBOTT LABORATORIES   (United States)

^e Abbott   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; PLACEBO;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; ASSESSMENT IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DEMYELINATING DISEASE; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LUPUS LIKE SYNDROME; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPPORTUNISTIC INFECTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SKIN CANCER; TUBERCULOSIS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BACK PAIN; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HEALTH STATUS; HUMANS; IMMUNOLOGIC FACTORS; MALE; PAIN MEASUREMENT; PROGNOSIS; RECOVERY OF FUNCTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 84859496711     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200358     Document Type: Article

References (29)

1. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)
2. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6. (Pubitemid 37409337)
3. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
4. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
5. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011;70:896-904.
6. van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922-9.
7. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008;59:1270-8.
8. Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52. (Pubitemid 351281269)
9. van der Heijde DM, Revicki DA, Gooch KL, et al. Physical function, disease activity and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009;11:R124.
10. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5. (Pubitemid 351281268)
11. Martín-Mola E, Sieper J, Leirisalo-Repo M, et al. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010;28:238-45.
12. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
13. Huang F, Zhu J, Zhang L, et al. Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab. Clin Rheumatol 2007;26:920-6. (Pubitemid 46951290)
14. de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009;61:1484-90.
15. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70. (Pubitemid 38658395)
16. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002-8.
17. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
18. Lord PA, Farragher TM, Lunt M, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010;49:563-70.
19. Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011;70:973-81.
20. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011;13:94.
21. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
22. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. (Pubitemid 32758236)
23. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-8.
24. Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of spondyloarthritis international society (asas) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68:1-44.
25. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
26. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti- TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6. (Pubitemid 41487242)
27. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009;68:1863-9.
28. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-91. (Pubitemid 351988090)
29. Schipper LG, Fransen J, den Broeder AA, et al. Time to achieve remission determines time to be in remission. Arthritis Res Ther 2010;12:R97.